Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

rts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

(1) VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone

Contacts:

Jennifer Snyder (media) Kyle Kuvalanka (investors)

(617) 444-1439 (617) 761-4734

NOTE TO EDITORS: This press release is also available under the Media section of the Company's website at: http://www.millennium.com


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
(Date:7/24/2014)... 24, 2014 Amgen (NASDAQ: AMGN ) ... results on Tuesday, July 29, 2014, after the close of ... a conference call with the investment community at 2 p.m. ... Robert A. Bradway , chairman and chief executive officer, and ... audio of the conference call will be simultaneously broadcast over ...
(Date:7/24/2014)... Inc. (NYSE MKT: IG), a New Jersey based specialty generic ... the second quarter ended June 30, 2014. Second ... million in the second quarter of 2014, an increase of ... revenues of $13.3 million for the six months ended June ... in 2013 , Total revenues generated from the sale ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
(Date:7/27/2014)... 2014 This is a professional ... Dutasteride (CAS 164656-23-9) industry. The report firstly reviews ... its classification, application and manufacturing technology. The report ... Dutasteride (CAS 164656-23-9) listing their product specification, capacity, ... report further analyzes quantitatively 2009-2014 global and China’s ...
(Date:7/27/2014)... July 27, 2014 The report ... in Aviation - Market Analysis (Commercial Aviation And ... Pneumatic, Hydraulic, Mechanical) - Forecasts 2014 - 2019." ... are expected to shape the market during the ... and technology trends that are currently prevailing in ...
(Date:7/27/2014)... News) -- Couples aren,t more likely to get divorced ... new research finds. The study only looks at ... play a direct role in affecting whether couples stay ... speak against fears that women,s growing educational advantage over ... Schwartz, lead author of the study, said in an ...
(Date:7/27/2014)... July 27, 2014 Alta Resources ... outsourcing (BPO) for Fortune 500 brands, announced today that ... its locations in Wisconsin, California, Florida and the Philippines. ... several health-insurance clients, which have seasonal ramp-ups that require ... (AEP), November 2014 through February 2015. As more consumers ...
(Date:7/27/2014)... 27, 2014 The Institute of Safe ... adverse events such as Xarelto bleeding side-effects reported after ... out numbered the complaints filed for its competitor Pradaxa, ... for Xarelto increased to nearly 1 million prescriptions per ... early 2012, the ISMP noted in its latest issue ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 2Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 4Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 5
... chronic hepatitis C are at risk of suffering from ... weeks from commencement of treatment, says the researchers in a ... Science (IOVS)in the January 2007 issue. ,Researchers from ... in diameter of blood vessels and the velocity of ...
... that suggests a link between a particular gene named ... journal, Neurobiology of Aging, published the results of the ... implicated in causing Alzheimer’s disease. ,This research now ... raises the possibility that occurrence of herpes infection earlier ...
... have to prescribe medicines by their generic names instead of ... ,"We have issued a letter in this regard to all ... and dispensaries," Singh told IANS. ,The doctors ... not the brand names. Failure to do so would call ...
... Leading pharmaceutical company Lupin Ltd has received tentative approval ... its generic drug Sertraline Hydrochloride for// treatment of major ... will be the AB-rated generic equivalent of Pfizer's Zoloft ... ,"The company intends to launch the generic (drug) ...
... were thought to be far cleaner and healthier as compared ... not true- inner cities are a haven// for unhealthy habits ... smoking and disease rates and dietary habits to understand the ... that towns such as Merthyr Tydfil in Wales happened to ...
... be used for 15 minutes before sleeping to treat insomnia ... based company Helicor, is under clinical trial on 100 patients ... heartbeat by regulated deep breathing, said the online edition of ... several other conditions including anxiety and panic attacks, is said ...
Cached Medicine News:Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... Liquichek ToRCH Plus Control ... used to monitor the performance ... serology instruments and assays. A ... control allow you to monitor ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: